Navigation Links
Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation
Date:11/11/2008

y double-blind, anti-arrhythmic, morbidity-mortality study in patients with AF. It was conducted in more than 550 sites in 37 countries and enrolled a total of 4,628 patients.

Previous results from the landmark ATHENA study have shown that dronedarone on top of standard therapy decreased the combined primary endpoint of cardiovascular hospitalization or death from any cause by a statistically significant 24 percent (p<0.001) as compared to placebo and reduced the risk of cardiovascular hospitalization by 25 percent (p<0.001). These results were achieved with a favorable safety profile.

The patients studied in ATHENA were either 75 years of age or older (with or without cardiovascular risk factor) either below 75 years of age with at least one additional cardiovascular risk factor (hypertension, diabetes, previous cerebrovascular event, left atrium size greater than 50 mm or left ventricular ejection fraction lower than 40 percent). Patients with decompensated heart failure (NYHA class IV) were excluded. Patients were randomized to receive dronedarone 400 mg BID or placebo, with a maximum follow-up of 30 months.

The ATHENA study objectives were to show a potential benefit of dronedarone on the primary composite endpoint of all-cause mortality combined with cardiovascular hospitalization as compared to placebo. The pre-specified secondary endpoints were death from any cause, cardiovascular death and hospitalisation for cardiovascular reasons. The pre-specified safety endpoint was the incidence of treatment emergent adverse events (between first study drug intake and last study drug intake plus 10 days) including: all adverse events, serious adverse events, adverse events leading to study drug discontinuation.

About dronedarone (Multaq(R))

Dronedarone (Multaq(R)) is an investigational treatment and the only Anti-Arrhythmic Drug (AAD) to have shown a significant reduction in morbidity and mortality in AF/AFL patients with a favourable
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
2. ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
3. ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
4. Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation
5. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
6. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
7. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
8. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
9. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
10. Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture
11. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  Hill-Rom (NYSE: ... Providence Health ( Renton, WA ), the ... expands the companies, existing relationship as Hill-Rom now becomes ... Bariatric capital bed frame and surface products. ... systems in the U.S.  It operates 34 hospitals, 475 ...
(Date:9/23/2014)... Sept. 23, 2014  MEDIMETRIKS PHARMACEUTICALS today announced ... Resnick have been elected to Medimetriks, Board ... Mr. Lary, who will serve on Medimetriks, Audit ... experience to the Company.  Mr. Lary is currently ... a leading institutional investment firm.  Mr. Lary is ...
(Date:9/23/2014)... Sept. 23, 2014   COTA, Inc. today ... $7 million Series A funding round led by Horizon ... is the first big data platform designed by practicing ... analysis for cancer care in support of healthcare,s new ... to expand development of the COTA platform, hire biostatisticians, ...
Breaking Medicine Technology:Hill-Rom Announces Seven-Year, Sole-Source Contract with Providence Health 2Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4
... MARINO, Calif. March 25, 2011 VG Energy, ... VRAL ), announced today that it ... to verify lab results on a large scale for the development ... VG Energy has developed proprietary technology, with results ...
... Ltd. (Nasdaq: SVA ), a leading provider ... Weidong Yin, President and CEO, and Ms. Helen Yang, ... UBS Greater China Healthcare Corporate Day.  The conference will ... March 28th to March 29.  The Sinovac team will ...
Cached Medicine Technology:VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 2VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 3VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 4Sinovac Participates in UBS Greater China Healthcare Corporate Day 2
(Date:9/23/2014)... (PRWEB) September 23, 2014 Mel Frank, ... about cultivating, growing and harvesting marijuana. He is perhaps ... the field and he’ll be leading a special elective ... am to 5:00 pm at Oaksterdam University ... law, botany and nomenclature, harvesting and manicuring, and identifying ...
(Date:9/23/2014)... that FDG-PET technology is less accurate in diagnosing ... infections like histoplasmosis or tuberculosis are common. ... lead to unnecessary tests and surgeries for patients, ... Histoplasmosis and other fungal diseases are linked to ... and are found in soils. , The study ...
(Date:9/23/2014)... San Diego, CA (PRWEB) September 23, 2014 ... website daily regarding all the latest information from the ... announced on September 5, that its Private Label Jalapeno ... glass and small stones. Publix Jalapeno Bagels ... in the bakery department. , Taking into consideration ...
(Date:9/23/2014)... 2014 (HealthDay News) -- A test used to diagnose lung ... certain lung infections are more common, a new analysis says. ... through the use of what,s known as functional imaging. For ... is used, according to the study authors. Cancerous tumors ... parts of the lungs that don,t have cancer, according to ...
(Date:9/23/2014)... 23, 2014 Grinnell Mutual seeks ... projects in the Midwest. Working Together Making It ... non-profit organizations with projects positively impacting their communities. ... marketplace make their communities a better places,” said ... Community Relations Barb Baker. “Their leadership—as coaches, as ...
Breaking Medicine News(10 mins):Health News:Special Elective Course Added to Oaksterdam University Schedule; Unique Opportunity to Learn From the “Godfather of Cannabis” Mel Frank on September 27, 2014 2Health News:Study questions accuracy of lung cancer screens in some geographic regions 2Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:Grinnell Mutual Invites Submissions for Innovative, Collaborative Local Projects in Its Second Annual Working Together Making It Better Promotion 2
... death rates, longer hospital stays and greater costs , , ... (GI) bleeding admitted to hospitals on weekends are more ... to two studies that analyzed U.S. patient data. ... upper gastrointestinal hemorrhage (NVUGIH) admitted on weekends were 36 ...
... of Your Mental Health Talk Radio www.blogtalkradio.com/yourmentalhealth when ... Men Are From Mars, Women Are From Venus ... new book When Mars and Venus Collide: Improving Relationships ... on Thursday, March 5th at 8 PM EST/5 PM ...
... Hit Unprecedented Lows; Approximately Half of Hospitals UnprofitableANN ... margin of U.S. hospitals has fallen to zero ... hospital finances published today. Driven largely by ... apparent in all types of hospitals - small, ...
... than 52,000 patients from eight countries has shown that ... improvements and greater patient satisfaction. , The findings, ... International Journal of Clinical Practice , show that 53 ... less than seven per cent, the target set by ...
... users with Zix CorporationDALLAS, March 2 Zix Corporation ... Blue Shield of Massachusetts (BCBSMA) today announced a contract ... Zix Corporation and Blue Cross Blue Shield of Massachusetts ... entering its sixth year. Under the contract terms, ...
... Edwin Ishoo , MD, an Otolaryngologist and facial ... the use of both minimally invasive and non-invasive techniques ... procedures implemented by Dr. Ishoo are also designed to ... activities as soon as possible."We are committed to using ...
Cached Medicine News:Health News:Weekend Admission May Be Riskier for GI Bleeding 2Health News:John Gray Will Discuss His New Book Why Mars and Venus Collide 2Health News:Thomson Reuters Study Tracks Impact of Recession on Hospitals 2Health News:Thomson Reuters Study Tracks Impact of Recession on Hospitals 3Health News:Insulin drug study shows significant improvements in more than 52,000 diabetic patients 2Health News:Insulin drug study shows significant improvements in more than 52,000 diabetic patients 3Health News:Zix Corporation and Blue Cross Blue Shield of Massachusetts Expand the Industry's Largest e-Prescribing Program 2Health News:Edwin Ishoo MD Providing Non-Invasive Cosmetic Procedures, Minimizing Recovery Time 2
... 210, Carl Zeiss has created a surgical microscope ... for ophthalmic surgery. Its wide range of uses ... and it offers new functions to improve depth ... integrated assistant's microscope the OPMI VISU 210 is ...
Blood grouping tubes are available in two formulations, ACD-A, ACD-B or with a CPDA solution. Blood grouping tubes are for blood grouping determinations and also for cell preservation....
MONOJECT Brown Stopper...
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
Medicine Products: